Newswise — March 22, 2022An innovative technique called burst wave lithotripsy (BWL) may provide an effective, more accessible alternative for noninvasive treatment of kidney stones, according to initial human studies reported in The Journal of Urology®, an Official Journal of the American Urological Association (AUA). The journal is published in the Lippincott portfolio by Wolters Kluwer.

Using focused ultrasound bursts to break up kidney stones, BWL provides a promising new approach to avoiding the high costs and healthcare burden of kidney stone treatment, according to the report by Jonathan Harper, MD, of University of Washington School of Medicine and colleagues. They write, "New BWL technology successfully fragmented stones of a variety of sizes, locations and densities to under two-millimeter fragments within 10 minutes with negligible tissue injury."

Toward new office-based treatment approach for kidney stones

Kidney stones are a very common condition, affecting 1 in 10 Americans at a cost of $10 billion per year. While many stones pass on their own, other treatments are sometimes needed. Some fairly small stones can be treated using a technique called extracorporeal shock wave lithotripsy (ESWL), using shock waves to break up the stones so that they will be more likely to pass on their own. The ESWL procedure is performed in a hospital or clinic, typically with the patient under sedation.

In contrast to the shock waves used in ESWL, the BWL procedure uses "short harmonic bursts" of ultrasound energy – potentially allowing the stones to be broken up in a shorter procedure without the need for sedation or anesthesia. Pre-clinical studies supported the effectiveness of BWL in breaking up experimental stones of varying size and composition.

For the next step in developing the procedure, Dr. Harper and colleagues performed initial studies in human patients with kidney stones. The patients were undergoing a surgical procedure, called ureteroscopy, that is used to treat larger stones. Before that treatment, the stones were treated with a short period of BWL – no longer than 10 minutes. Using the ureteroscope, the researchers were able to directly observe how well the ultrasound waves worked in breaking up stones, as well as observing any injury to the kidney tissues.

In the study, BWL was used in 19 patients to target 25 confirmed stones. Overall, a median of 90% of the stone volume was completely broken up (comminuted) within the brief treatment period. Thirty-nine percent of stones were completely fragmented while 52% were partially fragmented.

Most of the stone fragments measured less than two millimeters – small enough that they would be easily able to pass on their own, without much pain. Examination through the ureteroscope showed mild or no tissue injury related to the BWL procedure, consisting mainly of mild bleeding.

For several reasons, BWL could be an important practical advance in the management of kidney stones. Many patients make multiple visits to the emergency department while waiting for definitive treatment of their kidney stones, often requiring opioids for pain management. Some patients require repeated treatment, even after surgery or ESWL. "The ability to noninvasively break stones and expel the fragments in awake patients at first presentation in the ED or clinic has the potential to provide just-in-time treatment leading to a reduction of the overall pain, cost and resource burden associated with a stone event," researchers write.

The new results "are a step toward an office-based lithotripsy for awake patients," Dr. Harper and coauthors conclude. They plan further studies toward determining whether the BWL technique can meet their ultimate goal of a "noninvasive, 30-minute treatment in the clinic without anesthesia."

The BWL technology was licensed to SonoMotion which is developing a commercial version of the technology and is in the midst of separate clinical trials.

Click here to read "Fragmentation of Stones by Burst Wave Lithotripsy in the First 19 Humans"

DOI: 10.1097/JU.0000000000002446

###

About The Journal of Urology®

The Official Journal of the American Urological Association (AUA), and the most widely read and highly cited journal in the field, The Journal of Urology® brings solid coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of urology. This premier journal presents investigative studies on critical areas of research and practice, survey articles providing brief editorial comments on the best and most important urology literature worldwide and practice-oriented reports on significant clinical observations. The Journal of Urology® covers the wide scope of urology, including pediatric urology, urologic cancers, renal transplantation, male infertility, urinary tract stones, female urology and neurourology.

About the American Urological Association

Founded in 1902 and headquartered near Baltimore, Maryland, the American Urological Association is a leading advocate for the specialty of urology, and has nearly 24,000 members throughout the world. The AUA is a premier urologic association, providing invaluable support to the urologic community as it pursues its mission of fostering the highest standards of urologic care through education, research and the formulation of health care policy. To learn more about the AUA visit: www.auanet.org

About Wolters Kluwer

Wolters Kluwer (WKL) is a global leader in professional information, software solutions, and services for the clinicians, nurses, accountants, lawyers, and tax, finance, audit, risk, compliance, and regulatory sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with advanced technology and services.

Wolters Kluwer reported 2019 annual revenues of €4.6 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 19,000 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.

Wolters Kluwer provides trusted clinical technology and evidence-based solutions that engage clinicians, patients, researchers and students with advanced clinical decision support, learning and research and clinical intelligence. For more information about our solutions, visit https://www.wolterskluwer.com/en/health and follow us on LinkedIn and Twitter @WKHealth.

For more information, visit www.wolterskluwer.com, follow us on TwitterFacebookLinkedIn, and YouTube.

SEE ORIGINAL STUDY